<unk>  improves markers of combined hyperlipidemia, effectively reducing LDL and triglycerides and improving HDL levels. The main effect on cardiovascular morbidity is in patients with the metabolic syndrome, the features of which are attenuated by<unk> . Studies show that in patients with impaired glucose tolerance,<unk>  may delay progress to diabetes, and in those with insulin resistance it slowed progress in the HOMA severity marker. In addition, a prospective observational study of dyslipidemic patients with diabetes or hyperglycemia showed that<unk>  significantly reduces haemoglobin A1c (HbA1c) concentration as a function of baseline HbA1c levels, regardless of concurrent use of antidiabetic drugs.
Bezafibrate
Clofibrate
Fenofibrate
Ezetimibe
Lovastatin
Atorvastatin
Fibrate
Rosuvastatin